Professor James Spicer
Professor of Experimental Cancer Medicine
Research interests
- Cancer
Contact details
Biography
James Spicer is Professor of Experimental Cancer Medicine within the Comprehensive Cancer Centre.
Research
Cancer Early Phase Trials Unit
Led by Professor James Spicer, Dr Debashis Sarker and Dr Rebecca Kristeleit, the Cancer Early Phase Trials Unit focuses on the discovery and development of novel molecular and cellular cancer immunotherapies.
Experimental Oncology
The Experimental Oncology Programme is focused on the development of new treatments for solid tumours.
Project status: Ongoing
Cancer Immunology & Immunotherapy
Cancer Immunology represents a broad field of research that studies host-tumour interactions as therapeutic targets in the treatment of cancer.
Project status: Ongoing
King’s Health Partners ECMC
King’s Health Partners ECMC focuses particularly on new Molecular and Cellular cancer immunotherapies, building on recent translation of agents discovered in King’s laboratories.
News
King's part of new London-based Advanced Therapy Treatment Centre
King’s College London, Guy’s and St Thomas’ NHS Foundation Trust and King’s College Hospital NHS Foundation Trust have been awarded funding to form the London...
Trial shows promise for new antibody cancer treatment
The first ever clinical trial of a new class of immunotherapy for cancer has shown promising results that could benefit patients who do not respond to...
COVID reforms in cancer care and research could have long-term benefits
A new review led by Professor James Spicer considers the reforms in cancer care and research made due to the pandemic, arguing that some have left a positive...
Study shows promising results for immunotherapy targeting skin cancer
A new class of immunotherapy shows promising results for fighting the most aggressive form of skin cancer.
Experimental cancer treatments receive funding boost
King's Health Partners (KHP) Experimental Cancer Medicine Centre (ECMC) has had its funding renewed for the next five years.
King's immuno-oncology spin-out gains £30m funding
A spin-out company created by Professor Sophia Karagiannis and Professor James Spicer has secured £30.75 million to support further development and clinical...
King's immuno-oncology company receives £1 million grant to develop treatments for cancer
A spin-out company created by Professor Sophia Karagiannis and Professor James Spicer has secured a second Smart Grant of £1 million from the UK’s innovation...
New class of immunotherapy drug shows promise in early clinical trial
Results are disclosed today from the world’s first clinical trial of a new class of immunotherapy drugs which fight cancer using one of the body’s natural...
Features
Transforming cancer care at King's
King’s is the site of future breakthroughs, transforming cancer care and therapies through innovative research. An injection of philanthropic donations...
Spotlight
Researchers develop and trial new class of immunotherapy drug to fight cancer
Immunotherapy works by stimulating the body’s natural defence system to attack cancer.
Research
Cancer Early Phase Trials Unit
Led by Professor James Spicer, Dr Debashis Sarker and Dr Rebecca Kristeleit, the Cancer Early Phase Trials Unit focuses on the discovery and development of novel molecular and cellular cancer immunotherapies.
Experimental Oncology
The Experimental Oncology Programme is focused on the development of new treatments for solid tumours.
Project status: Ongoing
Cancer Immunology & Immunotherapy
Cancer Immunology represents a broad field of research that studies host-tumour interactions as therapeutic targets in the treatment of cancer.
Project status: Ongoing
King’s Health Partners ECMC
King’s Health Partners ECMC focuses particularly on new Molecular and Cellular cancer immunotherapies, building on recent translation of agents discovered in King’s laboratories.
News
King's part of new London-based Advanced Therapy Treatment Centre
King’s College London, Guy’s and St Thomas’ NHS Foundation Trust and King’s College Hospital NHS Foundation Trust have been awarded funding to form the London...
Trial shows promise for new antibody cancer treatment
The first ever clinical trial of a new class of immunotherapy for cancer has shown promising results that could benefit patients who do not respond to...
COVID reforms in cancer care and research could have long-term benefits
A new review led by Professor James Spicer considers the reforms in cancer care and research made due to the pandemic, arguing that some have left a positive...
Study shows promising results for immunotherapy targeting skin cancer
A new class of immunotherapy shows promising results for fighting the most aggressive form of skin cancer.
Experimental cancer treatments receive funding boost
King's Health Partners (KHP) Experimental Cancer Medicine Centre (ECMC) has had its funding renewed for the next five years.
King's immuno-oncology spin-out gains £30m funding
A spin-out company created by Professor Sophia Karagiannis and Professor James Spicer has secured £30.75 million to support further development and clinical...
King's immuno-oncology company receives £1 million grant to develop treatments for cancer
A spin-out company created by Professor Sophia Karagiannis and Professor James Spicer has secured a second Smart Grant of £1 million from the UK’s innovation...
New class of immunotherapy drug shows promise in early clinical trial
Results are disclosed today from the world’s first clinical trial of a new class of immunotherapy drugs which fight cancer using one of the body’s natural...
Features
Transforming cancer care at King's
King’s is the site of future breakthroughs, transforming cancer care and therapies through innovative research. An injection of philanthropic donations...
Spotlight
Researchers develop and trial new class of immunotherapy drug to fight cancer
Immunotherapy works by stimulating the body’s natural defence system to attack cancer.